Health Care & Life Sciences » Biotechnology | Bavarian Nordic A/S

Bavarian Nordic A/S | Balance Sheet

Fiscal year is January-December. All values DKK Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
532
980
1,058
1,900
2,584
2,317
Total Accounts Receivable
124
206
162
158
48
86
Inventories
234
122
91
147
112
101
Other Current Assets
11
11
93
77
27
4
Total Current Assets
900
1,319
1,404
2,283
2,770
2,508
Net Property, Plant & Equipment
323
337
326
326
348
519
Long-Term Note Receivable
1
1
1
1
-
1
Intangible Assets
105
109
108
83
33
33
Other Assets
-
-
-
-
1
-
Total Assets
1,452
1,887
1,989
2,824
3,153
3,061
ST Debt & Current Portion LT Debt
8
2
2
2
2
Accounts Payable
114
59
70
72
83
Income Tax Payable
-
-
-
-
1
Other Current Liabilities
267
523
518
678
161
Total Current Liabilities
389
583
590
752
247
Long-Term Debt
72
33
31
30
400
Provision for Risks & Charges
15
19
25
25
-
Deferred Taxes
124
122
150
130
-
Total Liabilities
476
635
647
806
646
Common Equity (Total)
976
1,252
1,342
2,017
2,506
Total Shareholders' Equity
976
1,252
1,342
2,017
2,506
Total Equity
976
1,252
1,342
2,017
2,506
Liabilities & Shareholders' Equity
1,452
1,887
1,989
2,824
3,153

About Bavarian Nordic A/S

View Profile
Address
Hejreskovvej 10A
Kvistgaard CR 3490
Denmark
Employees -
Website http://www.bavarian-nordic.com
Updated 07/08/2019
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases.